News About: R&D
Seegene succeeds in developing reagents using AI for the first time
Seegene succeeded in developing a molecular diagnosis reagent only in 4 days with its self-developed automated AI reagent development system.
Seegene(CEO Jong-Yoon Chun), a molecular diagnosis company, announced on t...
Oscotec applies for U.S. clinical 2a IND of its rheumatoid arthritis treatment
Oscotec(CEo Jung-Geun Kim), a new drug developing company, announced on the 26th that the company applied for a IND for a clinical 2a study to the U.S. FDA as completing Phase I SAD(single ascending dose) & MAD(multip...
KPBMA establishes private-public AI Novel Drug Development Support Center by 2019
The ‘Artificial Intelligence(AI) Novel Drug Development Support Center’ jointed established by private and public organizations will be launched in 2019 in Korea, which attract attention of the pharmaceutical industry...
Kuhnil first reveals Phase III clinical trial for Omega-3 & Rosuvastatin combination drug
Kuhnil(CEO Young-Joong Kim) announced the Phase III clinical trial result for ‘Rosumega SC,’ a dyslipidemia combination drug, was published in the SCI-level international journal ‘Clinical Therapeutics’ on 6 December....
Foreign CROs hot in Korea, accounting for more than 30% of total CROs in Korea
In the Korean clinical study market, foreign CROs(contract research organization) are reportedly getting popular.
According to the ‘Korea Clinical Trail Industry Statistics’ published by the Korea National Enterprise...
Korea follows only 71.4% of U.S. drug development technology
It was analyzed the Korea’s technological level of drug development was 71.4% of what the U.S. had and the technological gap was 4.1 years.
The Ministry of Health and Welfare and the Korea Health Industry Development...
Standigm reveals novel drug discovering services using new AI technology
A novel drug discovering company based on artificial intelligence ‘Standigm(CEO Jin-Han Kim)’ announced the company selected as the next-generation pharmaceutical and biotechnology company at the ‘23th Bio-Europe,’ an...
Phase III clinical trials accounted for the most of total clinical trials in Korea
Since the number of approvals for clinical trial plan was rapidly increasing for the past several years, it is now common to hear ‘clinical trial’ around us.
Thus, the Ministry of Food and Drug Safety(MFDS) analyzed ...
‘Serious’ polarization of R&D investment among innovative pharmaceutical companies
It was criticized polarization of R&D investments was getting intensified among innovative pharmaceutical companies certified to have excellent new drug development and overseas expansion capabilities.
While there is...
225 pipelines of biologics being developed in Korea
There were reportedly 225 cases of clinical trials for biologics being developed in Korea.
According to the Ministry of Food and Drug Safety(MFDS), there were ongoing clinical trials for total 225 products at the end...
